Loss of p53 function at late stages of tumorigenesis confers ARF-dependent vulnerability to p53 reactivation therapy

Cancer development is driven by activated oncogenes and loss of tumor suppressors. While oncogene inhibitors have entered routine clinical practice, tumor suppressor reactivation therapy remains to be established. For the most frequently inactivated tumor suppressor p53, genetic mouse models have de...

Full description

Saved in:
Bibliographic Details
Published in:Proc Natl Acad Sci U S A
Main Authors: Klimovich, Boris, Mutlu, Samet, Schneikert, Jean, Elmshäuser, Sabrina, Klimovich, Maria, Nist, Andrea, Mernberger, Marco, Timofeev, Oleg, Stiewe, Thorsten
Format: Artigo
Language:Inglês
Published: National Academy of Sciences 2019
Subjects:
Biological Sciences
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6825290/
https://ncbi.nlm.nih.gov/pubmed/31611375
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1910255116
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items